title: Antagonism of the prostaglandin E receptor EP4 inhibits metastasis and enhances NK function.
abstract: Cyclooxygenase-2 (COX-2) is associated with aggressive breast cancers. The COX-2 product prostaglandin E(2) (PGE(2)) acts through four G-protein-coupled receptors designated EP1-4. Malignant and immortalized normal mammary epithelial cell lines express all four EP. The EP4 antagonist AH23848 reduced the ability of tumor cells to colonize the lungs or to spontaneously metastasize from the mammary gland. EP4 gene silencing by shRNA also reduced the ability of mammary tumor cells to metastasize. Metastasis inhibition was lost in mice lacking either functional Natural Killer (NK) cells or interferon-gamma. EP4 antagonism inhibited MHC class I expression resulting in enhanced ability of NK cells to lyse mammary tumor target cells. These studies support the hypothesis that EP4 receptor antagonists reduce metastatic potential by facilitating NK-mediated tumor cell killing and that therapeutic targeting of EP4 may be an alternative approach to the use of COX inhibitors to limit metastatic disease.
authors.affiliation: Department of Pathology, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
authors.forename: Namita
authors.initials: N
authors.lastname: Kundu
authors.forename: Xinrong
authors.initials: X
authors.lastname: Ma
authors.forename: Dawn
authors.initials: D
authors.lastname: Holt
authors.forename: Olga
authors.initials: O
authors.lastname: Goloubeva
authors.forename: Suzanne
authors.initials: S
authors.lastname: Ostrand-Rosenberg
authors.forename: Amy M
authors.initials: AM
authors.lastname: Fulton
mesh_terms: D000818:Animals; D045744:Cell Line, Tumor; D005260:Female; D005434:Flow Cytometry; D007694:Killer Cells, Natural / Q000276:immunology*; D008325:Mammary Neoplasms, Experimental / Q000235:genetics / Q000276:immunology* / Q000378:metabolism*; D051379:Mice; D009361:Neoplasm Invasiveness / Q000235:genetics* / Q000276:immunology; D034741:RNA, Small Interfering; D018078:Receptors, Prostaglandin E / Q000037:antagonists & inhibitors* / Q000235:genetics; D058309:Receptors, Prostaglandin E, EP4 Subtype; D020133:Reverse Transcriptase Polymerase Chain Reaction
chemical_list: C545651:Ptger4 protein, mouse; D034741:RNA, Small Interfering; D018078:Receptors, Prostaglandin E; D058309:Receptors, Prostaglandin E, EP4 Subtype
references.citation: J Biol Chem. 2007 Jun 8;282(23):16959-68
references.pmid: 17401137
references.citation: J Cell Physiol. 1989 Apr;139(1):93-9
references.pmid: 2540214
references.citation: Cancer Res. 2005 Jun 1;65(11):4496-9
references.pmid: 15930264
references.citation: Cancer Res. 2007 Mar 1;67(5):2015-21
references.pmid: 17332329
references.citation: J Invest Dermatol. 2006 Jan;126(1):205-11
references.pmid: 16417238
references.citation: Cancer Res. 2006 Mar 15;66(6):2923-7
references.pmid: 16540639
references.citation: Cancer Res. 2002 Jan 15;62(2):506-11
references.pmid: 11809702
references.citation: J Clin Immunol. 1983 Oct;3(4):295-315
references.pmid: 6140268
references.citation: Physiol Rev. 1999 Oct;79(4):1193-226
references.pmid: 10508233
references.citation: Int J Cancer. 2001 Sep 1;93(5):681-6
references.pmid: 11477578
references.citation: Life Sci. 2003 Dec 5;74(2-3):391-5
references.pmid: 14607267
references.citation: Am J Pathol. 2002 Dec;161(6):2065-78
references.pmid: 12466123
references.citation: Oncogene. 2007 May 10;26(21):3006-19
references.pmid: 17130837
references.citation: Cancer Res. 1998 Jan 15;58(2):362-6
references.pmid: 9443418
references.citation: Cancer Res. 2007 May 1;67(9):4507-13
references.pmid: 17483367
references.citation: Cancer Res. 2002 Feb 1;62(3):632-5
references.pmid: 11830510
references.citation: Curr Opin Pharmacol. 2005 Apr;5(2):204-10
references.pmid: 15780832
references.citation: J Immunol. 2000 Jan 1;164(1):361-70
references.pmid: 10605031
references.citation: Cell. 1998 May 29;93(5):705-16
references.pmid: 9630216
references.citation: Cancer Res. 1985 Oct;45(10):4779-84
references.pmid: 4027966
references.citation: J Clin Invest. 2001 Oct;108(8):1229-35
references.pmid: 11602631
references.citation: Proc Natl Acad Sci U S A. 2004 Jan 13;101(2):591-6
references.pmid: 14688410
references.citation: J Biol Chem. 2008 Apr 25;283(17):11155-63
references.pmid: 18319253
references.citation: Biochim Biophys Acta. 2008 Jun;1783(6):1211-9
references.pmid: 18346464
references.citation: J Cell Physiol. 1996 Nov;169(2):401-9
references.pmid: 8908208
references.citation: Cancer Res. 1993 Mar 15;53(6):1322-7
references.pmid: 8443812
references.citation: Exp Cell Res. 2003 Oct 1;289(2):265-74
references.pmid: 14499627
references.citation: J Urol. 2005 Jan;173(1):56-60
references.pmid: 15592025
references.citation: Cancer Immunol Immunother. 2005 Oct;54(10):981-7
references.pmid: 15891886
references.citation: Cancer Res. 2000 Mar 1;60(5):1306-11
references.pmid: 10728691
references.citation: Cancer Res. 2006 Oct 1;66(19):9665-72
references.pmid: 17018624
references.citation: Cancer Res. 1991 Apr 15;51(8):2047-50
references.pmid: 1849040
references.citation: Cancer Res. 1999 Oct 15;59(20):5093-6
references.pmid: 10537280
references.citation: BMC Cancer. 2006 Jan 30;6:27
references.pmid: 16445867
references.citation: Cancer Res. 2005 Oct 15;65(20):9304-11
references.pmid: 16230392
references.citation: Cancer Res. 2006 Mar 15;66(6):3106-13
references.pmid: 16540660
references.citation: Cancer Sci. 2003 Jul;94(7):618-21
references.pmid: 12841871
references.citation: Nat Med. 2001 Sep;7(9):1048-51
references.pmid: 11533709
references.citation: J Exp Med. 2003 Jan 20;197(2):221-32
references.pmid: 12538661
references.citation: J Clin Endocrinol Metab. 2003 Jun;88(6):2810-6
references.pmid: 12788892
references.citation: Mod Pathol. 2008 Jan;21(1):15-21
references.pmid: 17906615
references.citation: Cell Immunol. 1986 Apr 15;99(1):108-18
references.pmid: 2944621
references.citation: J Biol Chem. 2008 Feb 8;283(6):3433-3444
references.pmid: 18083712
references.citation: Cancer Res. 2002 Apr 15;62(8):2343-6
references.pmid: 11956094
references.citation: J Biol Chem. 2003 Sep 12;278(37):35451-7
references.pmid: 12824187
references.citation: J Clin Invest. 2003 Mar;111(5):727-35
references.pmid: 12618527
references.citation: Int J Cancer. 2007 Jul 15;121(2):232-40
references.pmid: 17290397
references.citation: Lancet. 1977 Sep 24;2(8039):624-6
references.pmid: 71446
references.citation: Exp Cell Res. 2007 Aug 15;313(14):2969-79
references.pmid: 17631291
references.citation: Carcinogenesis. 2001 Dec;22(12):2001-4
references.pmid: 11751431
references.citation: Cancer Res. 2002 Jan 1;62(1):28-32
references.pmid: 11782353
references.citation: Prostaglandins Other Lipid Mediat. 2007 Feb;83(1-2):112-20
references.pmid: 17259077